PCI Biotech - Småprat 2 2020 (PCIB)

[squadron]

Se sliden! Show figures! “Virker på alt”

Photochemical Internalization for Intracellular Drug Delivery. From Basic...

Sixty-one-year-old female with metastatic squamous cell carcinoma (SCC) to the torso (back) treated with PCI of bleomycin. The primary identified disease was in the tongue base with nodal involvement (cervical and axillary). The patient underwent radiotherapy and multiple rounds of chemotherapy for her tongue base carcinoma, which failed to control the disease. Left-hand column: the shielding around the lesion after including 10mm of macroscopically healthy looking tissue to eliminate any risk of micro-infiltration, followed by PCI surface illumination. Right hand column: the “target lesion” on day -14, day 28 and month 3, where complete response was achieved. For month 3, selective surgical biopsies acquired from the centre and peripheries were found to be tumour-free.

Figure 11

Sample of seven patients that presented with advanced and/or recurrent solid malignancies that were subjected to the PCI surface illumination protocol. (A) 56-year-old male with chondroblastic osteosarcoma in the right mandible. The patient has failed multiple surgical resections with reconstructions and multiple rounds of subsequent chemo-radiation. The patient was treated with 0.25 mg/kg TPCS2a-induced PCI and had complete response of all the illuminated sarcoma of the R face. (B) 45-year-old male with squamous cell carcinoma of the neck with metastasis to the lungs and liver, who failed multiple conventional interventions. The patient was treated with 1.0 mg/kg TPCS2a-induced PCI and had partial response © 61-year-old female with metastatic squamous cell carcinoma (SCC) to the torso (back). The primary malignancy was a tongue base SCC with metastasis to the cervical and axillary lymph nodes. She had multiple failed interventions to the primary site. The patient was treated with 0.5 mg/kg TPCS2a-induced PCI and had complete response. (D) 46-year-old female with advanced metastatic ductal carcinoma to the torso (anterior) brain, spine, lungs and liver. The patient’s metastatic torso lesions were treated with 0.5 mg/kg TPCS2a-induced PCI and had complete response. (E) 72-year-old female with metastatic (chemo-resistant) ductal carcinoma to the arm. The primary breast cancer also metastasised to the axillary and cervical lymph nodes. The patient’s metastatic arm lesion was treated with 1.0 mg/kg TPCS2a-induced PCI and had partial response. (F) 35-year-old male with squamous cell carcinoma of the floor of mouth and neck. This patient failed surgery, chemo-radiation and photodynamic therapy. The cancer metastasised to the right lung and required pneumonectomy. The patient’s extensive disease was treated with 1.0 mg/kg TPCS2a-induced PCI and had complete response of the treated areas. (G) 73-year-old male with oral squamous cell carcinoma. This patient failed multiple surgical interventions with reconstruction, as well as chemo-radiation. The patient’s extensive disease was treated with 0.5 mg/kg TPCS2a-induced PCI and had complete response of the treated areas.

[Hpbjorn]

Både “wow” og “fy f***” på samme tid…!

[squadron]

Jepp! Det er denne dritten selskapet VÅRT prøver å bekjempe. Jeg heier på dem hele veien til mål

[Longtrader]

litt tidlig oppgang klar til i morgen

Klarer dere nå å knipe igjen salg så blir det bra

[Columna]

Oslo (Norway), 26 March 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has informed the company that a new US patent will be granted early April 2020. The US patent covers the use of fima Vacc in combination with a new important class of vaccine adjuvants called toll like receptor agonists.

Toll like receptor agonists (TLR agonists) is a diverse class of molecules that can be used for enhancing immune responses to several types of vaccines. TLR agonists have similarities to molecules present in various types of infectious agents, like viruses and bacteria, and can act as adjuvants to alert the immune system of a possible infection, thereby activating the immune system. The combination of TLR agonists with PCI Biotech’s vaccine technology, fima Vacc , has been shown to be effective for enhancing cellular immune responses that are important for the effect both of therapeutic and prophylactic vaccines. The US patent to be granted in April 2020 gives broad coverage for the combination of TLR agonists with the fima Vacc technology.

TLR agonists represent a new important class of vaccine adjuvants that are being developed with many new vaccine candidates. This US patent is therefore important for PCI Biotech’s partnering efforts and it also provides intellectual property of importance for our ability to potentially generate an internal future vaccine pipeline, said Per Walday, CEO of PCI Biotech.

As part of PCI Biotech’s strategy for applying the PCI technology for therapeutic cancer vaccines, several global patent applications were filed in 2013 and 2014. Today’s announced US patent secure protection until 2035 and this patent application is still pending in Europe and key Asian markets.

About fima Vacc This novel vaccine technology applies a unique mode of action, triggered endosomal release of antigens, to enhance the cytotoxic effect essential for therapeutic cancer vaccines as well as for several types of vaccines against viral and parasitic infections. fimaVacc works in synergy with several other state-of-the-art vaccination technologies, and is especially effective in combination with some types of TLR agonists. The fima Vacc programme aims to enhance the cellular immune responses that are important for the therapeutic and prophylactic effect of vaccines, and the fima Vacc technology has proven excellent preclinical efficacy with protein- and peptide-based vaccines. The technology has shown particularly strong CD8 T-cell immune responses, which are important for therapeutic vaccination, as well as enhanced helper (CD4) T-cell and antibody responses.

PCI Biotech successfully translated the vaccination technology into humans through a Phase I study in healthy volunteers that was completed in May 2019. The study covered more than 90 subjects and established the tolerability of fima Vacc across a wide range of doses. The immune results provided proof-of-concept and demonstrates fima Vacc ‘s potential to enhance overall T-cell responses, by demonstrating improvement of the immunogenicity of vaccines in healthy volunteers.

Effective induction of cytotoxic T-cells will be critical to realise the huge potential of therapeutic cancer vaccines, and is also important for vaccination against some viral and parasitic infections, but vaccines often fail to generate such responses. Insufficient delivery of vaccine antigens to the appropriate presentation pathway in the immune cells may be one of the main reasons for weak cytotoxic T-cell responses. The fima Vacc technology has the potential to effectively enhance vaccine presentation through these pathways.

Contact information:
Per Walday, CEO
pw@pcibiotech.no
Mobile: +47 917 93 429

About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fima Chem (enhancement of chemotherapeutics for localised treatment of cancer), fima Vacc (T-cell induction technology for therapeutic vaccination), and fima NAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fima Chem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fima Vacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fima NAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

[sjog]

Nytt patent godkjent, caset styrker seg fra dag til dag.

[Snoeffelen]

This US patent is therefore important for PCI Biotech’s partnering efforts and it also provides intellectual property of importance for our ability to potentially generate an internal future vaccine pipeline, said Per Walday, CEO of PCI Biotech.

Passer vel bedre å kommentere på småprattråden. Kommenterte det samme på fundamentaltråden. Så kan vi fortsette diskusjonen her.

Anywayz, kan være en viktig brikke som falt på plass mtp å få til avtaler på fimaVACC.

[Bonusfrelst]

Det virker som PCIB har begynt å børsmelde når de får patenter. Gjorde ikke det før. Men dette er søknader som ble sendt inn i 2014/15?

[Columna]

PCI Biotech vil få nytt patent i USA - aksjen stiger

[TheLion]

Next melding FimaVac at de samarbeide med BP mht Covid19 , eller …

Ja, jeg vet PW sa ikke noe om dette før. Men med patent på plass endrer kanskje verden?

[JAXI]

TLR-agonister har likheter med molekyler som finnes i forskjellige typer smittestoffer, som virus og bakterier, og kan fungere som hjelpestoffer for å varsle immunforsvaret om en mulig infeksjon, og dermed aktivere immunsystemet. Kombinasjonen av TLR-agonister med PCI Biotechs vaksineteknologi, fima Vacc, har vist seg å være effektiv for å styrke cellulære immunresponser som er viktige for effekten av terapeutiske og profylaktiske vaksiner. Det amerikanske patentet som ble gitt i april 2020 gir bred dekning for kombinasjonen av TLR-agonister med fima Vacc-teknologien.

dette er jo MEGET bra !!! enda en STERK verfisering at teknologien er banebrytende.

[Longtrader]

Der er utrolig mange som er fornøyd med 33kr, vel . Det er ikke sikkert dere kommer inn igjen til samme pris, selv i dette børsklima.

[nordpolen]

Hvis man skal massevaksinere med FimaVacc-teknologien og denne “band aid like medical device” - krever det at man dekker seg til i sin helhet, eller gjelder det kun det lokale området der vaksinen er satt?

[TheLion]

Bare hvor vaccin blitt satt. (overarm)

[JAXI]

kan ikke skjønne annet enn at AZ kommer på banen hær !

FimaVACC kan booste AZ sin check point inhibitor og ta opp kampen med Keytruda.
FimaNAc løser leveringen av naken mRNA

Dette er teknologier som er morgendagens medisiner og det ikke bare innen kreft!

[Geoinvestor]

TLR-agonister har likheter med molekyler som finnes i forskjellige typer smittestoffer, som virus og bakterier , og kan fungere som hjelpestoffer for å varsle immunforsvaret om en mulig infeksjon, og dermed aktivere immunsystemet. Kombinasjonen av TLR-agonister med PCI Biotechs vaksineteknologi, fima Vacc, har vist seg å være effektiv for å styrke cellulære immunresponser som er viktige for effekten av terapeutiske og profylaktiske vaksiner .

Kan Pcib sin teknologi kombineres med trvx sine virus i vaksiner? Trvx har vel også samarbeid med AZ. Oppkjøp av begge?

[Temlor]

Bra volym och stigning, >700000 första timmen.

[JAXI]

Kan Pcib sin teknologi kombineres med trvx sine virus i vaksiner? Trvx har vel også samarbeid med AZ. Oppkjøp av begge?

har tenkt samme tanken tidligere… slik jeg ser det kan fimaVACC iallefall kombineres med TG og kanskje oxo ONCOS

TG Mutant RAS neoantigen vaccine – Available for partnering

Peptide-based cancer vaccines activate cancer specific T – cell immune-responses

Mutant RAS proteins are neoantigen and drivers for development of cancer. RAS mutations are exclusively found in cancer cells and are therefore cancer specific targets for attacking cancer immunologically.

Peptides are not immunogenic by themselves and need an adjuvant that can trigger the peptide immunization process resulting in activation of the desired anti-cancer specific T cells. The quality of the immune reaction to peptides is completely dependent on the adjuvant.

By targeting the central cancer neoantigen mutant RAS and using the right type of adjuvant Targovax hope to succeed in developing a clinically efficient immunotherapy – which will benefit all patients with RAS mutated cancers. Targovax’s RAS peptides are small proteins which can be produced chemically in quantities of many kilograms. They are also very stable and can be stored for several years.

SUCCESSFUL CLINICAL PROOF OF CONCEPT
► Phase I study in healthy volunteers – vaccination with HPV E7 long peptides
The results show that tolerable treatments with the fimaVACC technology in combination with a state of the art adjuvant ( Hiltonol )

fimaVACC
" Effective induction of cytotoxic T-cells will be critical to realise the huge potential of therapeutic cancer vaccines, and todays vaccines often fail to generate such responses. One of the main reasons is likely insufficient delivery of vaccine antigens to the appropriate presentation pathway in the immune cells. The fima Vacc technology has the potential to effectively enhance vaccine presentation through these pathways. "

** Det er en sterk vitenskapelig begrunnelse for å kombinere CPI (Check Point Inhibitotors) med fimaVACC -teknologien: fimaVACC øker antallet T-celler indusert av kreftvaksiner mens CPI forhindrer svulsten i å unndra seg immunresponsen.

Kan ikke skjønne annet enn at TG02 in combination with the immune checkpoint inhibitor Keytruda + adjuvant and fimaVACC ville kunne blitt en mega suksess

[olafalo]

[Longtrader]

Nå datt en del tradere av i går,

og endel selger på melding og håper den detter ned igjen.

SÅ Hold !!! Så får vi reprising.